ATL II decreased the proliferation and viability of human colorectal cancer cells by disrupting the LncRNA XIST/miR-30a-5p/ROR1 signaling pathway, reducing cancer cells’ chemosensitivity and improving the efficacy of chemotherapy [61]. Here, ROR1 is linked to cancer.